Pair page
5-Amino-1MQ with GW-0742
Mechanism-tag overlap and published literature for 5-Amino-1MQ and GW-0742, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
nnmt-inhibitor
ppar-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying 5-Amino-1MQ and GW-0742 have published these mechanism-level observations. Not a co-administration recommendation.
5-Amino-1MQ inhibits nicotinamide N-methyltransferase, preserving NAD+ and SAM pools; combining with PPARδ agonism pushes metabolic flux toward oxidative phosphorylation. Preclinical-only combination.
Quick facts
5-Amino-1MQ
GW-0742
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2024 | 5-Amino-1MQ | Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024. PMID: 39161060. (Pharmacokinetic characterization of 5A1MQ after IV, oral, and SubQ dosing in DIO m… PMID 39161060 | preclinical, in vivo |
| 2018 | 5-Amino-1MQ | Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. PMID: 2… PMID 29155147 | preclinical, in vivo |
| 2017 | 5-Amino-1MQ | Neelakantan H, Wang HY, Vance V, Hommel JD, McHardy SF, Watowich SJ. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J Med Chem. 2017;60(12):5015-5028. PMID: 28493686. PMID 28493686 | mechanism / discovery |
| 2017 | 5-Amino-1MQ | Pissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends Endocrinol Metab. 2017;28(5):340-353. PMID: 28291578. PMID 28291578 | pharmacology |
| 2022 | 5-Amino-1MQ | Brightwell CR, Latham CM, Thomas NT, Keeble AR, Murach KA, Fry CS. A glitch in the matrix: the pivotal role for extracellular matrix remodeling during muscle hypertrophy. Am J Physiol Cell Physiol. 2022;323(3):C763-C771. PMID: 35876283. (Satellite-cell / NNMT context.) PMID 35876283 | research article |
| 2021 | 5-Amino-1MQ | Campagna R, Pozzi V, Sartini D, Salvolini E, Brisigotti V, Molinelli E, Campanati A, Offidani A, Emanuelli M. Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers. Cancers (Basel). 2021;13(19):4943. PMID: 34638428. PMID 34638428 | research article |
| 2021 | 5-Amino-1MQ | Roberti A, Fernández AF, Fraga MF. Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. Mol Metab. 2021;45:101165. PMID: 33453418. PMID 33453418 | research article |
| 2019 | 5-Amino-1MQ | Neelakantan H, Brightwell CR, Graber TG, Maroto R, Wang HL, McHardy SF, Papaconstantinou J, Fry CS, Watowich SJ. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Ph… PMID 30885768 | research article |
| 2018 | 5-Amino-1MQ | Komatsu M, Kanda T, Urai H, Kurokochi A, Kitahama R, Shigaki S, Ono T, Yukioka H, Hasegawa K, Tokuyama H, Kawabe H, Wakino S, Itoh H. NNMT activation can contribute to the development of fatty liver disease by modulating the NAD+ metabolism. Sci Rep. 2018;8(1):8637. PMID: 298721… PMID 29872148 | research article |
| 2015 | 5-Amino-1MQ | Hong S, Moreno-Navarrete JM, Wei X, Kikukawa Y, Tzameli I, Prasad D, Lee Y, Asara JM, Fernandez-Real JM, Maratos-Flier E, Pissios P. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med. 2015;21(8):887-894. PMID: 261… PMID 26168293 | research article |
| 2014 | 5-Amino-1MQ | Kraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT, Pirinen E, Pulinilkunnil TC, Gong F, Wang YC, Cen Y, Sauve AA, Asara JM, Peroni OD, Monia BP, Bhanot S, Alhonen L, Puigserver P, Kahn BB. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nat… PMID 24717514 | research article |
| 2013 | 5-Amino-1MQ | Ulanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol. 2013;9(5):300-306. PMID: 23455543. PMID 23455543 | research article |
| 2008 | GW-0742 | Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F. Activation of pe… PMID 18285555 | human trial, Phase 2 |
| 2005 | GW-0742 | Graham TL, Mookherjee C, Suckling KE, Palmer CN, Patel L. The PPARδ agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis. 2005;181(1):29-37. PMID: 15939051. (GW-0742 atherosclerosis data.) PMID 15939051 | preclinical, in vivo |
| 2005 | GW-0742 | Planavila A, Rodríguez-Calvo R, Jové M, Michalik L, Wahli W, Laguna JC, Vázquez-Carrera M. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;65(4):832-841. PMID: 15721862. (GW-0742 cardiac-h… PMID 15721862 | preclinical, in vivo |
| 2003 | GW-0742 | Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR Jr, Sternbach DD. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta) — synthesis… PMID 12699745 | mechanism / discovery |
| 2012 | GW-0742 | Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012;12(3):181-195. PMID: 22318237. (Comprehensive review of PPARs and cancer risk — the central safety-framing source for the class.) PMID 22318237 | review |
| 2026 | GW-0742 | WADA. 2026 World Anti-Doping Code Prohibited List. Section S4.5 — Metabolic Modulators. World Anti-Doping Agency. Effective January 1, 2026. | regulatory / registry |
| 2018 | GW-0742 | Palomer X, Barroso E, Pizarro-Delgado J, Peña L, Botteri G, Zarei M, Aguilar D, Montori-Grau M, Vázquez-Carrera M. PPARβ/δ: a key therapeutic target in metabolic disorders. Int J Mol Sci. 2018;19(3):913. PMID: 29558390. PMID 29558390 | research article |
| 2016 | GW-0742 | Tan NS, Vázquez-Carrera M, Montagner A, Sng MK, Guillou H, Wahli W. Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ. Prog Lipid Res. 2016;64:98-122. PMID: 27665713. PMID 27665713 | research article |
| 2010 | GW-0742 | Wagner KD, Wagner N. Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther. 2010;125(3):423-435. PMID: 20026354. PMID 20026354 | research article |
| 2008 | GW-0742 | Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. AMPK and PPARδ agonists are exercise mimetics. Cell. 2008;134(3):405-415. PMID: 18674809. PMID 18674809 | research article |
| 2007 | GW-0742 | Hollingshead HE, Killins RL, Borland MG, Girroir EE, Billin AN, Willson TM, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-beta/delta (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis. 2007;28(12):2641-26… PMID 17693662 | research article |
| 2006 | GW-0742 | Barish GD, Narkar VA, Evans RM. PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006;116(3):590-597. PMID: 16511591. PMID 16511591 | research article |
Related pair pages
More research context
Frequently asked
Have 5-Amino-1MQ and GW-0742 been studied together?
Researchers have published mechanistic-level co-administration discussion of 5-Amino-1MQ and GW-0742. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do 5-Amino-1MQ and GW-0742 share?
5-Amino-1MQ and GW-0742 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of 5-Amino-1MQ and GW-0742?
5-Amino-1MQ: Not approved. GW-0742: Never entered clinical trials. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on 5-Amino-1MQ and GW-0742?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the 5-Amino-1MQ profile and the GW-0742 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026